Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Iomab-B vs Conventional Care in Older R/R AML
NCT02665065Phase 3Active, not recruiting
- Sponsor
- Actinium Pharmaceuticals, Inc.
- Start
- Jun 2016
- Primary completion
- Jun 2022
- Modality
- Monoclonal Antibodies
- Countries
- 2
01
Overview
A Phase 3 trial of apamistamab in acute myeloid leukemia (AML), sponsored by Actinium Pharmaceuticals, Inc.. Started Jun 2016; status: active, not recruiting.
02
Drugs
apamistamab
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT02665065.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02665065.